Literature DB >> 3065729

An attempt to explain disordered immunity and hypogammaglobulinemia in B-CLL.

G Dighiero1.   

Abstract

Most CLL cases correspond to proliferation of a B-cell clone characterized by: low amounts of surface Ig (SIg); presence of receptors for mouse red blood cells; expression of a 67 Kd antigenic determinant (CD5) initially described to be a pan-T cell antigen. These peculiar characteristics differentiate the CLL B lymphocyte from B lymphocytes proliferating in other B-cell malignancies. These so-called CD5 + B cells constitute a minority of B cells in adults, although they predominate during foetal life. This latter fact induced a majority of authors to assume that CLL B lymphocytes correspond to proliferation of an immature B-cell clone. However, this hypothesis does not explain the particular high frequency with which hypogammaglobulinemia and autoimmune phenomena directed against blood cell components are found in B-CLL, as well as the difficulty to include CD5 antigen in most differentiation pathways of B-cells. In this work, we shall discuss the available evidence coming from Ly 1-B cells (mouse counterpart of CD5 B cells), indicating that these cells correspond to a separate B lineage. We shall also discuss the evidence for hypogammaglobulinemia being mainly a B cell defect caused by dilution or inhibition of normal CD5 negative B cells and disordered autoimmunity as a consequence of a disturbance of the idiotypic network, which normally antagonizes autoimmune clones.

Entities:  

Mesh:

Year:  1988        PMID: 3065729

Source DB:  PubMed          Journal:  Nouv Rev Fr Hematol


  2 in total

1.  Autoimmune thrombocytopenia: a complication of fludarabine therapy in the treatment of Waldenstrom's macroglobulinemia.

Authors:  Yujie Jiang; Hongjuan Peng; Xin Cui; Ying Zhou; Dai Yuan; Xiaohui Sui; Lingyan Zhang; Hongzhi Xu
Journal:  Int J Clin Exp Med       Date:  2014-12-15

Review 2.  The Expanding Field of Secondary Antibody Deficiency: Causes, Diagnosis, and Management.

Authors:  Smita Y Patel; Javier Carbone; Stephen Jolles
Journal:  Front Immunol       Date:  2019-02-08       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.